Enanta Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 145
- Market Cap
- $275.6M
- Introduction
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Clinical Trials
51
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (51 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants
- Conditions
- RSV InfectionDrug Drug Interaction
- Interventions
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 24
- Registration Number
- NCT06917508
- Locations
- 🇺🇸
ICON, plc, San Antonio, Texas, United States
A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
- Conditions
- RSV InfectionDrug Drug Interaction (DDI)
- Interventions
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06847464
- Locations
- 🇺🇸
ICON, plc, San Antonio, Texas, United States
A Study to Investigate the Effects of Zelicapavir (EDP-938) on QTc Interval in Healthy Adults
- Conditions
- RSV InfectionQTc Interval
- Interventions
- Drug: zelicapavir (therapeutic dose)Drug: zelicapavir (supratherapeutic dose)Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 72
- Registration Number
- NCT06601192
- Locations
- 🇺🇸
ICON Early Phase, LLC, San Antonio, Texas, United States
🇺🇸ICON, Lenexa, Kansas, United States
A Controlled Phase 2a Study to Evaluate the Efficacy of EDP-323 Against Respiratory Syncytial Virus Infection in a Virus Challenge Model
- Conditions
- RSV Infection
- Interventions
- Drug: EDP-323 Dose Regimen 1Drug: EDP-323 Dose Regimen 2Drug: Placebo
- First Posted Date
- 2023-12-14
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 142
- Registration Number
- NCT06170242
- Locations
- 🇬🇧
hVIVO Services Limited, London, United Kingdom
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
- First Posted Date
- 2022-11-15
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 231
- Registration Number
- NCT05616728
- Locations
- 🇺🇸
Torrance Clinical Research Institute, Lomita, California, United States
🇺🇸LA Universal Research Center, Inc., Los Angeles, California, United States
🇺🇸MedBio Trials - Miami, Aventura, Florida, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
XtalPi Secures $100 Million Partnership with Harvard's Gregory Verdine to Advance AI-Driven Drug Discovery
XtalPi has signed a Letter of Intent with DoveTree LLC, founded by Harvard Professor Gregory Verdine, for a collaboration worth $100 million upfront plus potential milestone payments exceeding $10 billion.
FDA Approves MAVYRET as First Treatment for Acute Hepatitis C with 96% Cure Rate in Eight Weeks
The U.S. FDA approved an expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir), making it the first and only oral eight-week pangenotypic treatment approved for people with acute hepatitis C virus infection.
Enanta Pharmaceuticals to Present Promising RSV Antiviral Data at Major European Medical Conferences
Enanta Pharmaceuticals will showcase data from its Phase 2 study of zelicapavir in RSV-infected children at the ESPID 2025 meeting, including new findings on PK/PD and viral clearance rates.
Enanta Pharmaceuticals' Zelicapavir Shows Promise in Pediatric RSV Trial
Enanta Pharmaceuticals' zelicapavir achieved a significant 0.7 log reduction in peak viral load on Day 9 in a Phase 2 trial for pediatric RSV patients.
Enanta's Zelicapavir Shows Promise in Phase 2 Pediatric RSV Trial
Enanta Pharmaceuticals reported positive topline results from its Phase 2 trial of zelicapavir for respiratory syncytial virus (RSV) in pediatric patients.
Enanta Pharmaceuticals' EDP-323 Shows Promise as First Antiviral Treatment for RSV
Enanta Pharmaceuticals' EDP-323, an investigational RSV inhibitor, demonstrates promising Phase 2a trial results, potentially becoming the first antiviral treatment for RSV infections.
Enanta Pharmaceuticals Gains Buy Ratings Amid RSV Drug Development Progress
Enanta Pharmaceuticals receives reiterated Buy ratings from JMP Securities and Robert W. Baird, citing promising RSV drug trial results and reduced competition.
Enanta Pharmaceuticals Awaits Phase II Zelicapavir Data for RSV
• Enanta Pharmaceuticals' Zelicapavir (EDP 938) is in Phase II trials (RSVPEDs and RSVHR) targeting RSV in pediatric and high-risk adult populations. • RSVPEDs, a Phase II trial in RSV-infected children aged 28 days to 3 years, has completed enrollment, with topline data expected in Q4 2024. • EDP-323, another RSV drug candidate from Enanta, showed statistically significant reductions in viral load and clinical symptoms in a Phase IIa human challenge study. • Enanta's financial stability is supported by $272.6 million in cash, cash equivalents, and marketable securities as of June 30, 2024, along with royalties from AbbVie's MAVYRET/MAVIRET.
Enanta's EDP-323 Shows Strong Efficacy in RSV Human Challenge Trial
Enanta Pharmaceuticals' EDP-323 demonstrated significant viral load reduction in a Phase 2a human challenge trial for Respiratory Syncytial Virus (RSV).